Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-501 Oral Suspension Compared to Placebo in Adult Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis

NCT03594227 is registered in ClinicalTrials.gov with Aclaris Therapeutics, Inc. as lead sponsor.

NCT NCT03594227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03594227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-501 Oral Suspension Compared to Placebo in Adult Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis
Lead sponsor
Aclaris Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 11, 2018
Completion date
June 18, 2019
Enrollment
87 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

alopecia